Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Post by iaheadoftheherdon Jun 24, 2014 8:58am

240 Views

Post# 22688591

Sernova Team Participates at Key US Life Sciences Event

Sernova Team Participates at Key US Life Sciences Event: 2014 BIO International Convention, San Diego

June 24th, 2014, 6:00 a.m. EST

LONDON, ONTARIO--(Marketwire – June 24th, 2014) - Sernova Corp. (TSX-V: SVA), a clinical stage company developing disruptive medical technologies for the long-term treatment of chronic diseases such as diabetes and haemophilia announced today that it is participating at the US BIO International Convention in San Diego, June 23-26th.

“This is an excellent occasion for Sernova to present to international institutions, pharma and potential collaborators to update attendees on our progress and pipeline”, remarked Dr. Philip Toleikis, President and CEO.

The convention is an important annual business development forum which allows high-level executives and influential decision makers attending BIO to liaise with key players in the industry, form partnerships, and evaluate emerging technologies.

“Sernova’s entire business development team is attending and has numerous one-on-one meetings booked to discuss its proprietary platform – many important collaborations mark their origins to BIO”, remarked Kevin Egan, chair of Sernova’s Business Advisory Board.

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary technologies.

For further information contact:

Philip Toleikis, Ph.D., President and CEO
Tel: (604) 961-2939
philip.toleikis@sernova.com
info@sernova.com
www.sernova.com

Ray Matthews & Associates
Ray Matthews
Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6
Tel: (604) 818-7778
www.raymatthews.ca

Bullboard Posts

This junior mining stock offers billions in market exposure